Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1313)	5/8/2002 12:36:49 PM
From: tuck	Read Replies (4) \| Respond to of 1475

>>CHARLESTOWN, Mass.--(BUSINESS WIRE)--May 8, 2002--BioTransplant (Nasdaq: BTRN - news) today announced a cost reduction program in order to advance the Company's product lines while streamlining operations and reducing overall costs. This program includes a reduction in workforce and spending cuts impacting all segments of the Company. "These cost reduction measures are expected to conserve the needed resources to continue developing BioTransplant's promising product lines," commented Dr. Elliot Lebowitz, CEO of BioTransplant. With these spending adjustments, BioTransplant expects to have operating capital for approximately three to four fiscal quarters. BioTransplant currently has the following clinical programs: - Siplizumab The Company's licensee, MedImmune, Inc., is conducting Phase II clinical trials for siplizumab, a proprietary anti-T cell monoclonal antibody for the treatment of psoriasis. - Eligix(TM) HDM Cell Separation System The Eligix System is a novel cell selection device for bone marrow transplantations, with applications in cancer, autoimmune diseases and transplantation. GAMBRO BCT is currently marketing the Eligix System in Europe. BioTransplant retains rights to North America and Japan and receives milestone payments, licensing fees and shares revenues elsewhere. - AlloMune(TM) System BioTransplant is conducting Phase I/II clinical trials with the AlloMune System, which will combine siplizumab with the HDM cell separation device to address the current problems of transplantation. The Company recently announced that a kidney transplant patient in a BioTransplant and Massachusetts General Hospital study is nearing the four-year milestone without immune suppressive drugs.<< snip I guess I prefer this to dilution at these prices. I wonder how the market will react given the vagueness here, and how soon we'll get details. Maybe the market already has reacted. Volume seems relatively low right now. Cheers, Tuck